Podcast: “Powerful Yet Unexplored”: Commit Biologics Tackles The Complement System

Mikkel Wandahl Pederson, CEO and chief scientific officer at Commit Biologics, discussed the company’s mission to harness the powerful complement system for the treatment of serious diseases.

In Vivo Podcast

Commit Biologics is a preclinical company developing a new class of therapeutics based on its Bispecific Complement Engager (BiCE) platform to treat autoimmune diseases and cancer.

Mikkel Wandahl Pederson, CEO and chief scientific officer at Commit Biologics. (Fotograf Esben Zøllner Olesen)

The company is focused on advancing BiCE, designed to activate the complement system and induce the highly selective killing of cells of interest.

Speaking to the In Vivo podcast, Wandahl Pederson explained that “the unique thing about Commit’s technology is of course the BiCE technology. The B molecules have a unique ability to engage the C1Q, which is the first protein in the [classical] complement cascade.”

Although the company is yet to have any candidates in the clinic, its next steps will involve generating proof-of-concept data over the next year and selecting a candidate with the greatest potential for pipeline development.

“It’s critical for us that we identify the right asset, the most promising one, the one that differentiates the most. So, we allow ourselves some time to think about that before actually selecting the final candidates that we want to push forward,” said Pederson. 

The biotech has secured a cash runway leading to an estimated mid-2027. After launching in May 2024 with €16m in seed funding from Bioqube Ventures and Novo Holdings, Commit secured a €5.5m seed financing extension in January 2025 from Belgian investment company Korys, bringing its total funding to €21.5m.

In Vivo spoke to Wandahl Pederson about Commit Biologics’ ambitious attitude as it continues to develop its BiCE technology and search for collaborations both academically and professionally.

Timestamps:

Overview of the complement system and its role in the immune system – 02:50

BiCE technology - 05:22

New antibody development strategies – 07:50

Regulatory and pipeline strategies – 10:01

Seed funding and future opportunities - 14:32

Career history -17:15

Challenges facing the company and the industry - 19:00

More from Podcasts

Podcast: Acuitas CSO On CRISPR Delivery Breakthrough And Next-Gen Lipid Nanoparticle Technology

 
• By 

In Vivo sits down with Ying Tam, CSO at Acuitas Therapeutics, to discuss the company's role in delivering the first personalized CRISPR treatment to an infant and the clinical implications of new lipid nanoparticle technologies.

Podcast: ADDF’s Karen Harris On Investing In Alzheimer’s Like A VC

 
• By 

A discussion with Karen Harris, CFO of the Alzheimer's Drug Discovery Foundation, about the foundation's investment strategy, biotech and investor sentiment at the recent BIO conference and what innovations give her hope for Alzheimer's patients.

Podcast: Brain+ CEO Discusses “Groundbreaking” Potential Of CST Assistant For Dementia Patients

 

Devika Wood, CEO of Brain+, explains the importance of developing health tech solutions for dementia and the growing need to both raise awareness and improve overall access to nondrug interventions like CST.

Podcast: Flagship’s Vision To Predict And Prevent Illness, With Raj Panjabi

 
• By 

Flagship Pioneering senior partner Raj Panjabi discusses shifting health care from reactive treatment to AI-powered prediction and prevention of disease before symptoms emerge.

More from Leadership

EU Medtech Outlook: The View From MedTech Europe Experts

 
• By 

MedTech Forum 2025 was less MDR-focused than in previous years, as macro issues and exogenous threats were forced further into the center of medtech business thinking.

‘Confident In Lorundrostat’s Promise’: Mineralys CEO Talks Trials And Next Steps

 

In a conversation with In Vivo, CEO Jon Congleton discusses Mineralys’s data-rich journey toward an NDA filing, the significance of recent trial wins and how its candidate may offer a dual benefit in blood pressure and renal protection.

Rising Leaders 2025: Neha Krishnamohan On Readying For Uncertainty In Biotech

 

Neha Krishnamohan, CFO of Artiva Biotherapeutics, brings Wall Street precision to biotech innovation, helping lead the company through a successful IPO while advancing NK cell therapies for cancer and autoimmune diseases.